White Lauren bought IMGN

February 12, 2024 · Form 4 insider transaction

White Lauren bought 295,975 shares of ImmunoGen, Inc., a transaction worth N/A. The trade was recorded as disposition to the issuer and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Acquired (buy-side)
Shares
295,975
Price
N/A
Total value
N/A
RoleOfficer
SecurityStock Option (Right to Buy)
Transaction codeD: Disposition to the issuer
Transaction dateFebruary 12, 2024
Filing dateFebruary 12, 2024
Shares owned after0
OwnershipDirect
10b5-1 planNo
AmendedNo

Footnotes

This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger").; At the effective time of the Merger (the "Effective Time"), each option to purchase shares of common stock, par value $.01 per share, of the Issuer ("Common Stock," and such option, a "Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $31.26, without interest (the "Merger Consideration") over the applicable exercise price per share of Common Stock under such Stock Option.

View the original Form 4 on SEC EDGAR